Cardiometabolic comorbidities in psoriasis and psoriatic arthritis

Research output: Contribution to journalReview articleResearchpeer-review

33 Citations (Scopus)

Abstract

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. There is solid epidemiologic evidence linking psoriasis and psoriatic arthritis (PsA) to cardiovascular risk factors and an increased risk of developing cardiovascular disease. Chronic inflammation, with shared pathways and cytokines common to metabolic syndrome, atherosclerosis and psoriasis, might provide the basis for the cardiovascular and metabolic comorbidities of psoriasis and PsA. The purpose of this manuscript is to review recent evidence about the epidemiology and underlying mechanisms of cardiovascular risk factors and cardiovascular disease in patients with psoriasis and/or PsA, the use of analytical determinations, physiologic measures and imaging techniques as surrogate biomarkers of atherosclerosis, endothelial dysfunction and cardiovascular disease in these patients, and the epidemiological and clinical data, including results of clinical trials, supporting a cardioprotective role of anti-inflammatory and disease-modifying treatment in psoriasis and PsA.
Original languageEnglish
Article number58
JournalInternational Journal of Molecular Sciences
Volume19
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • Atherosclerosis
  • Cardiovascular disease
  • Cardiovascular risk
  • Inflammation
  • Metabolic syndrome
  • Psoriasis
  • Psoriatic arthritis

Fingerprint Dive into the research topics of 'Cardiometabolic comorbidities in psoriasis and psoriatic arthritis'. Together they form a unique fingerprint.

  • Cite this